Access count of this item: 188

Files in This Item:
File Description SizeFormat 
jrr_rrt098.pdf117.75 kBAdobe PDFView/Open
Title: Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer.
Authors: Suzuki, Minoru  kyouindb  KAKEN_id
Kato, Ituro
Aihara, Teruhito
Hiratsuka, Junichi
Yoshimura, Kenichi
Niimi, Miyuki
Kimura, Yoshihiro
Ariyoshi, Yasunori
Haginomori, Shin-Ichi
Sakurai, Yoshinori  kyouindb  KAKEN_id
Kinashi, Yuko  kyouindb  KAKEN_id
Masunaga, Shin-Ichiro  kyouindb  KAKEN_id
Fukushima, Masanori
Ono, Koji
Maruhashi, Akira
Author's alias: 鈴木, 実
Keywords: boron neutron capture therapy
head and neck tumors
Issue Date: 1-Jan-2014
Publisher: Oxford University Press
Journal title: Journal of radiation research
Volume: 55
Issue: 1
Start page: 146
End page: 153
Abstract: We retrospectively review outcomes of applying boron neutron capture therapy (BNCT) to unresectable advanced or recurrent head and neck cancers. Patients who were treated with BNCT for either local recurrent or newly diagnosed unresectable head or neck cancers between December 2001 and September 2007 were included. Clinicopathological characteristics and clinical outcomes were retrieved from hospital records. Either a combination of borocaptate sodium and boronophenylalanine (BPA) or BPA alone were used as boron compounds. In all the treatment cases, the dose constraint was set to deliver a dose <10-12 Gy-eq to the skin or oral mucosa. There was a patient cohort of 62, with a median follow-up of 18.7 months (range, 0.7-40.8). A total of 87 BNCT procedures were performed. The overall response rate was 58% within 6 months after BNCT. The median survival time was 10.1 months from the time of BNCT. The 1- and 2-year overall survival (OS) rates were 43.1% and 24.2%, respectively. The major acute Grade 3 or 4 toxicities were hyperamylasemia (38.6%), fatigue (6.5%), mucositis/stomatitis (9.7%) and pain (9.7%), all of which were manageable. Three patients died of treatment-related toxicity. Three patients experienced carotid artery hemorrhage, two of whom had coexistent infection of the carotid artery. This study confirmed the feasibility of our dose-estimation method and that controlled trials are warranted.
Rights: © The Author 2013. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Therapeutic Radiology and Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
URI: http://hdl.handle.net/2433/182047
DOI(Published Version): 10.1093/jrr/rrt098
PubMed ID: 23955053
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.